A phase I study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor targeted therapies

PURPOSE: The PI3K/Akt/mTOR pathway is dysregulated in metastatic renal cell carcinoma (mRCC). Buparlisib is a pan-PI3K inhibitor with activity in advanced solid tumors. The primary aim of this study was to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of buparlisib a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: McKay, Rana R., De Velasco, Guillermo, Werner, Lillian, Bellmunt, Joaquim, Harshman, Lauren, Sweeney, Christopher, Rosenberg, Jonathan E., Hirsch, Michelle, Signoretti, Sabina, Van Allen, Eliezer, Walsh, Meghara, Vaishampayan, Ulka, McDermott, David F., Choueiri, Toni K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5567751/
https://ncbi.nlm.nih.gov/pubmed/27198170
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30056
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados